PhilippinesTuberculosis profile
Population  2014 99 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 10 (9–11) 10 (9.1–11)
Mortality (HIV+TB only) 0.08 (0.055–0.11) 0.08 (0.06–0.11)
Prevalence  (includes HIV+TB) 410 (360–470) 417 (367–471)
Incidence  (includes HIV+TB) 290 (250–320) 288 (254–324)
Incidence (HIV+TB only) 2.5 (2–3.2) 2.6 (2–3.2)
         
Case detection, all forms (%) 85 (76–97)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 2 (1.4–2.7) 21 (16–29)
MDR-TB cases among notified pulmonary
TB cases
4 600 (3 300–6 300) 6 500 (4 700–8 700)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 92 991   6 277
Pulmonary, clinically diagnosed 139 950    
Extrapulmonary 4 161    
       
Total new and relapse 243 379    
Previously treated, excluding relapses 24 057    
Total cases notified 267 436    
Among 97 578 new and relapse cases:
12 191 (12%) cases aged under 15 years; male:female ratio: 1.8
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 4 415 (5%) 20 196 (67%) 27 287
Laboratory-confirmed RR-/MDR-TB cases     3 000
Patients started on MDR-TB treatment ***     2 680
TB/HIV 2014 Number (%)
TB patients with known HIV status 53 354 (20)
HIV-positive TB patients 108 (<1)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 20 (19)
HIV-positive TB patients on antiretroviral therapy (ART) 53 (49)
HIV-positive people screened for TB 5 995  
HIV-positive people provided with IPT    
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (90) 216 250
Previously treated cases, excluding relapse, registered in 2013 (86) 2 924
HIV-positive TB cases, all types, registered in 2013    
RR-/MDR-TB cases started on second-line treatment in 2012 (43) 1 798
XDR-TB cases started on second-line treatment in 2012 (10) 10
Laboratories 2014  
Smear (per 100 000 population) 2.6
Culture (per 5 million population) 1.1
Drug susceptibility testing (per 5 million population) 0.2
Sites performing Xpert MTB/RIF 84
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 106
% Funded domestically 23%
% Funded internationally 39%
% Unfunded 37%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-04 Data: www.who.int/tb/data